{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:28Z","timestamp":1791993928602,"version":"4.4.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Clovis Oncology, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Molecularly targeted cancer therapy has rapidly changed the landscape of oncologic care, often improving patients\u2019 prognosis without causing as substantial a quality-of-life decrement as cytotoxic chemotherapy does. Nevertheless, targeted agents can cause side effects that may be less familiar to medical oncologists and that require the attention and expertise of subspecialists. In this review, we focus on hyperglycemia, which can occur with use of new anticancer agents that interact with cell proliferation pathways. Key mediators of these pathways include the tyrosine kinase receptors insulin growth factor receptor 1 (IGF-1R) and epidermal growth factor receptor (EGFR), as well as intracellular signaling molecules phosphatidylinositol 3-kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR). We summarize available information on hyperglycemia associated with agents that inhibit these molecules within the larger context of adverse event profiles. The highest incidence of hyperglycemia is observed with inhibition of IGF-1R or mTOR, and although the incidence is lower with PI3K, AKT, and EGFR inhibitors, hyperglycemia is still a common adverse event. Given the interrelationships between the IGF-1R and cell proliferation pathways, it is important for oncologists to understand the etiology of hyperglycemia caused by anticancer agents that target those pathways. We also discuss monitoring and management approaches for treatment-related hyperglycemia for some of these agents, with a focus on our experience during the clinical development of the EGFR inhibitor rociletinib.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0519","type":"journal-article","created":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T01:49:25Z","timestamp":1469843365000},"page":"1326-1336","source":"Crossref","is-referenced-by-count":77,"title":["Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management"],"prefix":"10.1093","volume":"21","author":[{"given":"Jonathan W.","family":"Goldman","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody A.","family":"Mendenhall","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Rettinger","sequence":"additional","affiliation":[{"name":"Endocrinology Medical Group of Orange County, Inc., Orange, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,7,29]]},"reference":[{"key":"2021122309533123500_B1","volume-title":"Eurostat. Causes of death statistics - statistics explained"},{"key":"2021122309533123500_B2","first-page":"1","article-title":"Deaths: Leading causes for 2010","volume":"62","author":"Heron","year":"2013","journal-title":"Natl Vital Stat Rep"},{"key":"2021122309533123500_B3","volume-title":"National Cancer Institute. Targeted cancer therapies fact sheet - National Cancer Institute"},{"key":"2021122309533123500_B4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122309533123500_B5","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122309533123500_B7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdt012","article-title":"Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)","volume":"24","author":"Chen","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309533123500_B8","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","article-title":"Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations","volume":"31","author":"Yang","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122309533123500_B10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10637-015-0217-7","article-title":"Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors","volume":"33","author":"Higano","year":"2015","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B11","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.ejca.2013.06.010","article-title":"An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours","volume":"49","author":"Sch\u00f6ffski","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122309533123500_B12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309533123500_B13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jhep.2013.09.008","article-title":"A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma","volume":"60","author":"Abou-Alfa","year":"2014","journal-title":"J Hepatol"},{"key":"2021122309533123500_B14","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1158\/1078-0432.CCR-10-3336","article-title":"A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors","volume":"17","author":"Atzori","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B15","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1002\/cncr.27459","article-title":"A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors","volume":"118","author":"Reidy-Lagunes","year":"2012","journal-title":"Cancer"},{"key":"2021122309533123500_B16","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309533123500_B18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-014-2391-2","article-title":"Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial","volume":"73","author":"Becerra","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309533123500_B19","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B20","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","article-title":"A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors","volume":"16","author":"Kurzrock","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B21","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for Research through Collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1078-0432.CCR-14-0303","article-title":"A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors","volume":"21","author":"Puzanov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","article-title":"Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors","volume":"21","author":"Jones","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122309533123500_B25","volume-title":"Zykadia (ceritinib) capsules [prescribing information]","year":"2014"},{"key":"2021122309533123500_B26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10637-014-0164-8","article-title":"A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma","volume":"33","author":"Goyal","year":"2015","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-13-152","article-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","volume":"13","author":"Goldman","year":"2013","journal-title":"BMC Cancer"},{"key":"2021122309533123500_B28","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","article-title":"A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer","volume":"19","author":"Socinski","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clbc.2013.12.012","article-title":"A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer","volume":"14","author":"Jhaveri","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"2021122309533123500_B30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2005.12.002","article-title":"Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial","volume":"52","author":"Moore","year":"2006","journal-title":"Lung Cancer"},{"key":"2021122309533123500_B31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-0452","article-title":"Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab","volume":"17","author":"Wadlow","year":"2012","journal-title":"The Oncologist"},{"key":"2021122309533123500_B32","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2015.33.15_suppl.8001","article-title":"Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive NSCLC patients","volume":"33","author":"Sequist","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B33","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10637-014-0082-9","article-title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"32","author":"Rodon","year":"2014","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1078-0432.CCR-13-1777","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"20","author":"Shapiro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","article-title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"key":"2021122309533123500_B37","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/jco.2011.29.15_suppl.3003","article-title":"Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B38","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/jco.2011.29.15_suppl.3022","article-title":"First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive AKT inhibitor GDC-0068","volume":"29","author":"Tabernero","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B39","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1158\/1078-0432.CCR-14-0868","article-title":"Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers","volume":"20","author":"Yap","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10637-015-0264-0","article-title":"Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group (MC1079)","volume":"33","author":"Ma","year":"2015","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B41","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.29363","article-title":"Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG Cooperative Group Trial (S1005)","volume":"121","author":"Ramanathan","year":"2015","journal-title":"Cancer"},{"key":"2021122309533123500_B42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122309533123500_B43","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"key":"2021122309533123500_B44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/ERC-13-0254","article-title":"Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate","volume":"20","author":"Kamp","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2021122309533123500_B45","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"2021122309533123500_B46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2021122309533123500_B47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","article-title":"Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"27","author":"Wolpin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"key":"2021122309533123500_B49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/bjc.2012.47","article-title":"Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum","volume":"106","author":"Yoon","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122309533123500_B50","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s10637-013-0028-7","article-title":"Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide","volume":"31","author":"Yoo","year":"2013","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B51","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O\u2019Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B52","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B53","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B54","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"2021122309533123500_B55","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B56","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br J Cancer"},{"key":"2021122309533123500_B57","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma","volume":"33","author":"Oza","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B58","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122309533123500_B59","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/0284186X.2011.589404","article-title":"Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma","volume":"51","author":"Lamm","year":"2012","journal-title":"Acta Oncol"},{"key":"2021122309533123500_B61","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/bjc.2013.530","article-title":"A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-na\u00efve castration-resistant prostate cancer","volume":"109","author":"Kruczek","year":"2013","journal-title":"Br J Cancer"},{"key":"2021122309533123500_B62","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clgc.2013.05.007","article-title":"A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer","volume":"11","author":"Armstrong","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"2021122309533123500_B63","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122309533123500_B64","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B65","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/JTO.0b013e31824de0d6","article-title":"Brief report: A phase II \u201cwindow-of-opportunity\u201d frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study","volume":"7","author":"Reungwetwattana","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2021122309533123500_B66","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B67","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10637-015-0218-6","article-title":"A phase 1 study of the sachet formulation of the oral dual PI3K\/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors","volume":"33","author":"Bendell","year":"2015","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B68","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/jco.2014.32.15_suppl.5513","article-title":"Phase II trial of GDC-0980 (dual PI3K\/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results","volume":"32","author":"Makker","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B69","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10637-013-0062-5","article-title":"Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer","volume":"32","author":"Britten","year":"2014","journal-title":"Invest New Drugs"},{"key":"2021122309533123500_B70","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","article-title":"First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122309533123500_B71","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309533123500_B72","volume-title":"Keytruda (pembrolizumab) for injection [prescribing information]","year":"2015"},{"key":"2021122309533123500_B73","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B74","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-13-0584","article-title":"Insulin signaling, resistance, and the metabolic syndrome: Insights from mouse models into disease mechanisms","volume":"220","author":"Guo","year":"2014","journal-title":"J Endocrinol"},{"key":"2021122309533123500_B75","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"2021122309533123500_B76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5732\/cjc.012.10263","article-title":"IGF-1R as an anti-cancer target\u2013trials and tribulations","volume":"32","author":"Chen","year":"2013","journal-title":"Chin J Cancer"},{"key":"2021122309533123500_B77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fendo.2014.00224","article-title":"IGF-IR targeted therapy: Past, present and future","volume":"5","author":"Janssen","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021122309533123500_B78","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2021122309533123500_B79","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/156800909789271495","article-title":"Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy","volume":"9","author":"Van der Veeken","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"2021122309533123500_B80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/157489212798357930","article-title":"Insulin-like growth factor: Current concepts and new developments in cancer therapy","volume":"7","author":"King","year":"2012","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"2021122309533123500_B81","first-page":"360","article-title":"Update on third-generation EGFR tyrosine kinase inhibitors","volume":"3","author":"Gray","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"2021122309533123500_B82","first-page":"576","article-title":"Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"2021122309533123500_B83","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309533123500_B84","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2337\/db13-0106","article-title":"Evidence for rapamycin toxicity in pancreatic \u03b2-cells and a review of the underlying molecular mechanisms","volume":"62","author":"Barlow","year":"2013","journal-title":"Diabetes"},{"key":"2021122309533123500_B85","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","article-title":"Pushing the envelope in the mTOR pathway: The second generation of inhibitors","volume":"10","author":"Vilar","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122309533123500_B86","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"2021122309533123500_B87","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122309533123500_B88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"2021122309533123500_B89","volume-title":"Afinitor (everolimus) tablets for oral administration afinitor disperz (everolimus tablets for oral suspension) [prescribing information]","year":"2016"},{"key":"2021122309533123500_B90","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"2021122309533123500_B91","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"2021122309533123500_B92","doi-asserted-by":"crossref","first-page":"e89561","DOI":"10.1371\/journal.pone.0089561","article-title":"Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes","volume":"9","author":"Kochupurakkal","year":"2014","journal-title":"PLoS One"},{"key":"2021122309533123500_B93","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1530\/EJE-13-0586","article-title":"Endocrine side effects of anti-cancer drugs: Effects of anti-cancer targeted therapies on lipid and glucose metabolism","volume":"170","author":"Verg\u00e8s","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2021122309533123500_B94","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309533123500_B95","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: A consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/11\/1326\/41875282\/oncolo_21_11_1326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/11\/1326\/41875282\/oncolo_21_11_1326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:26:02Z","timestamp":1640319962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/11\/1326\/6401267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,29]]},"references-count":95,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,7,29]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0519","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11,1]]},"published":{"date-parts":[[2016,7,29]]}}}